Enanta Pharmaceuticals INC Schedule 13G passive stakes

Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have collectively acquired a 4.97% stake in Enanta Pharmaceuticals, Inc., as disclosed in a Schedule 13G filing.

Farallon Capital Management, L.L.C. has filed a Schedule 13G, reporting beneficial ownership of 8.3% of Enanta Pharmaceuticals Inc. common stock as of June 30, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Enanta Pharmaceuticals Inc. following an internal realignment.

Deep Track Capital, LP and affiliated entities have reported a 6.78% beneficial ownership stake in Enanta Pharmaceuticals Inc. as of December 31, 2025.

Farallon Capital Management entities and individuals updated their beneficial ownership in Enanta Pharmaceuticals Inc., reflecting internal management changes within Farallon.

Millennium Management and affiliated entities have filed an amended Schedule 13G, reporting a 2.3% beneficial ownership in Enanta Pharmaceuticals, Inc. as of December 31, 2025.

Millennium Management and affiliates report a 4.1% beneficial ownership in Enanta Pharmaceuticals as of September 30, 2025.

Janus Henderson Group PLC and its affiliates have reported a significant beneficial ownership stake of 12.1% in Enanta Pharmaceuticals Inc.

Deep Track Capital, LP and its affiliates have reported a 5.33% beneficial ownership stake in Enanta Pharmaceuticals Inc., totaling 1,484,513 shares.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.8% beneficial ownership stake in Enanta Pharmaceuticals Inc. as of March 31, 2025, indicating a passive investment.

Farallon Capital and its affiliated entities have filed an amended Schedule 13G, reporting a collective beneficial ownership of 9.9% in Enanta Pharmaceuticals Inc. as of December 31, 2024.

Millennium Management LLC, along with its affiliates Integrated Core Strategies (US) LLC, Millennium Group Management LLC, and Israel A. Englander, have disclosed a collective passive beneficial ownership of 6.5% in Enanta Pharmaceuticals, Inc.